Navigation Links
Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
Date:4/9/2008

SAN CARLOS, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has ceased all negotiations with potential partners for its inhaled insulin programs as a result of new data analysis from ongoing clinical trials conducted by Pfizer Inc. An increase in the number of new cases of lung cancer was observed in inhaled insulin patients as compared to the control group. All new incidences of lung cancer were in patients that are former smokers.

"The concern over this new data analysis from ongoing clinical trials has resulted in the termination of all negotiations with potential partners," said Howard W. Robin, President and CEO of Nektar. "Fortunately, over the past year Nektar has significantly transformed its business, moving away from inhaled insulin. We have made great progress expanding our research efforts and have built a deep pipeline of novel partnered and proprietary drugs in various stages of development."

Nektar will cease all spending associated with its inhaled insulin programs and will not incur any additional charges related to this event.

The Exubera label was updated by Pfizer to contain the following safety information warning:

"In clinical trials of Exubera, there have been 6 newly diagnosed cases of primary lung malignancies among Exubera-treated patients, and 1 newly diagnosed case among comparator treated patients. There has also been 1 post-marketing report of a primary lung malignancy in an Exubera-treated patient. In controlled clinical trials of Exubera, the incidence of new primary lung cancer per 100 patient-years of study drug exposure was 0.13 (5 cases over 3900 patient-years) for Exubera-treated patients and 0.02 (1 case over 4100 p
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
2. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
3. OPKO Health and Pathogenics Announce Data Publication Demonstrating the Potential Utility of NCT in a Severe Eye Infection
4. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
5. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
6. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia
7. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
8. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
9. Potential Early Warning System for Lung Cancer Identified
10. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
11. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... According to the ... Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, ... (Immunology, Oncology) & by End User - ... provides a detailed overview of the major ... and strategies impacting the global glycomics enzymes, ...
(Date:9/30/2014)... A study using a relatively new imaging ... at the composition of carotid artery disease and has ... the disease, a leading cause of stroke. ... September 2010 and May 2012, was featured in the ... American College of Cardiology (JACC) Cardiovascular Interventions. Interventional ...
(Date:9/30/2014)... BRUNSWICK, N.J., Sept. 30, 2014 The ... Kessler Foundation and New Jersey Health Foundation (NJHF) ... and patient care programs has been announced by ... officer of Kessler Foundation and James M. ... "The experience of New Jersey Health ...
Breaking Medicine Technology:Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2
... Solutions, Inc., the industry leader in innovative shape ... Intramedullary Ankle Fusion Nail. Ankle fusion is performed ... ankle joints, to correct joint deformities or to ... patented design utilizes shape memory alloy technology to ...
... Aug. 9, 2011 Eli Lilly and Company (NYSE: ... EVISTA® (raloxifene HCl tablets) therapy for more than three ... & Opinion . The review includes summaries of previously ... on EVISTA use. EVISTA is indicated for the treatment ...
Cached Medicine Technology:MedShape Solutions Announces FDA 510(k) Clearance of Innovative Ankle Fusion Device 2MedShape Solutions Announces FDA 510(k) Clearance of Innovative Ankle Fusion Device 3Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 2Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 3Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 4Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 5Lilly Announces Review of Data on Long-Term Raloxifene Treatment for Postmenopausal Osteoporosis Published in Current Medical Research & Opinion 6
(Date:9/30/2014)... September 30, 2014 Dynamic health ... hampered growth in the Bread Production industry over ... consumers to moderate their consumption of a variety ... premium varieties shrunk the market for white loaf ... proactively responded by introducing more nutritious products to ...
(Date:9/30/2014)... A University of Maryland-led research team has been ... National Institutes of Health (NIH) to develop new ... further our understanding of how large networks of ... information. This knowledge will help researchers identify the ... drive behavior, like decision-making and speaking, and alterations ...
(Date:9/30/2014)... September 30, 2014 The American ... to help diabetics curb their sweet tooth, but the ... this September, suggests that zero-calorie sweeteners may actually ... diabetes. , The Weizmann Institute of Science in ... artificial sweeteners to mice, the mice developed glucose intolerance. ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set ... Nashville, Tennessee. RMS welcomes the launch of an entirely ... of a new treatment center for the Lung Institute. ... Institute to Nashville, the hope is to bring awareness ... diagnosed and undiagnosed. With Nashville being a hub for ...
(Date:9/30/2014)... -- Medicare should cover low-dose computed tomography lung cancer ... a coalition of more than 60 patient and medical ... Cancer Alliance, the Society of Thoracic Surgeons, the American ... American Society of Clinical Oncology, made its point in ... Medicare & Medicaid Services (CMS). Such screening reduces ...
Breaking Medicine News(10 mins):Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Bread Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... and the Fastest Growing Healthcare Staffing Company with over 100 million Dollars ... ... Jackson Healthcare (JH) has been named the 5th largest healthcare staffing ... Compiled each year by SIA, firms are ranked on the list ...
... for their prolonged seizures with the sedative propofol may ... New research presented at CHEST 2008, the 74th annual ... Physicians (ACCP), shows that the use of propofol as ... (RSE), prolonged seizures that do not respond to initial ...
... look at the effect of neighborhood greenness on ... the Indiana University School of Medicine, Indiana University-Purdue ... that higher neighborhood greenness is associated with slower ... year period, regardless of residential density. , "Previous ...
... psychiatric cases in Michigan,s rural areas, particularly among children and ... colleges of Osteopathic Medicine and Human Medicine meet each week ... , On a typical morning, doctors in MSU,s Department of ... far away as Cadillac or Marquette all without leaving ...
... channel blockers could inhibit Plavix action, study says , , ... drugs, which are widely prescribed for coronary conditions, might ... new study says. , Calcium channel blockers appear to ... said the report by Austrian physicians published online Oct. ...
... Brachytherapy Treatment, ST. LOUIS, Oct. 27 ... to deliver radioactive seed therapy,in the prostate. The ... stabilizes the prostate during procedures. With the gland ... images to map,and confirm placement of radiation., ...
Cached Medicine News:Health News:Jackson Healthcare Named 5th Largest Healthcare Staffing Company 2Health News:Jackson Healthcare Named 5th Largest Healthcare Staffing Company 3Health News:Anti-seizure drug could be fatal 2Health News:Neighborhood greenness has long term positive impact on kids' health 2Health News:Neighborhood greenness has long term positive impact on kids' health 3Health News:MSU doctors bring much-needed psychiatric care to rural areas via technology 2Health News:Common Heart Drugs May Hamper Blood Thinner 2Health News:Common Heart Drugs May Hamper Blood Thinner 3Health News:Doctors Test Advanced Tool for Treating Prostate Cancer 2
... Lomb PMMA Anterior Chamber Intraocular Lenses are ... in patients 60 years of age or ... removed by primary intracapsular cataract extraction; or ... a structural reason that the anterior chamber ...
... Amvisc Plus is the preferred viscoelastic ... viscoelastic that reliably works from the start ... unique, moderately cohesive profile of this viscoelastic ... vacuum forces associated with phacoemulsification remove only ...
... ENDOGEL is a sterile, non-pyrogenic solution ... is supplied in a disposable single ... fitting, delivering 0,85 ml. Sodium ... of repetitive chains of disaccharides, glucoronate, ...
... a sterile, non-pyrogenic, transparent viscoelastic preparation ... molecular weight (average molecular weight 4 ... 23 mg/mL of sodium hyaluronate 5000, ... N-acetylglucosamine and sodium glucuronate linked by ...
Medicine Products: